| Size | Price | Stock |
|---|---|---|
| 100 mg | Get quote | |
| 250 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-120805 |
| M.Wt: | 570.46 |
| Formula: | C30H18O12 |
| Purity: | >98 % |
| Solubility: |
Aurofusarin is a secondary metabolite. Aurofusarin catalytically inhibits topoisomerase II alpha, induces CYP1A1, p53, oxidative stress, DNA damage, and glutathione redox shift, intercalates into DNA, and causes S phase reduction accompanied by cytoskeletal/nuclear condensation. Aurofusarin disrupts intestinal epithelial barrier integrity, acts additively with deoxynivalenol, reduces mitochondrial activity, is cytotoxic to colon cells, and inhibits probiotic Gram-positive bacteria through outer membrane penetration without affecting Gram-negative bacteria. Aurofusarin can be used in research on colon cancer and bacterial infections[1][2][3][4][5][6][7][8].
In Vitro:Aurofusarin shows relatively low toxicity against Spodoptera frugiperda Sf9 insect cells in the MTT assay[1].
Aurofusarin (5-10 µM; 24-72 h) decreases the TEER of differentiated IPEC-J2 at 10 µM, with a maximum reduction of 83% after 72 h, whereas 5 µM had no effect and viability was unaffected[2].
Aurofusarin (5 µM; 24-48 h) combined with DON (6-Diazo-5-oxo-L-nor-Leucine) (HY-108357) additively reduces the TEER of differentiated IPEC-J2 at 24 and 48 h without affecting viability[2].
Aurofusarin (1-10 μM; 1 h) inhibits human topoisomerase II α catalytic activity at concentrations ≥1 μM in a cell-free decatenation assay[3].
Aurofusarin (10 μM; 24 h) increases CYP1A1 activity in HT29 cells[3].
Aurofusarin (0.01-10 μM; 24 h) reduces mitochondrial activity in HT29 and HCEC-1CT cells[3].
Aurofusarin (0.01-10 μM; 24-72 h) inhibits the proliferation of HT29 and HCEC-1CT cells, with HCEC-1CT responding at 0.1 μM after 72 h, and both cell lines being strongly inhibited at 10 μM[3].
Aurofusarin (5-10 μM; 1-24 h) induces p53 but not γ-H2AX in HT29 and HCEC-1CT cells, and disrupts actin cytoskeleton morphology, especially in HCEC-1CT cells[3].
Aurofusarin (5-10 μM; 24 h) reduces S-phase cells in HT29 cells without altering the cell cycle distribution of HCEC-1CT cells[3].
Aurofusarin (0.01-10 μM; 1 h) induces DNA strand breaks in HT29 cells at 1 μM and induces fpg-sensitive oxidative DNA damage at concentrations ≥0.1 μM[3].
Aurofusarin (0.01-10 μM; 1-3 h) induces reactive oxygen species in HT29 cells[3].
Aurofusarin (0.01-10 μM; 1-24 h) alters the glutathione redox state in HT29 cells, decreasing tGSH and increasing the GSSG/GSH ratio[3].
Aurofusarin (0.01-10 μM; 3-24 h) induces CYP1A1 transcription in HT29 cells, reaching 8.1-fold after 3 h at 5 μM and 6.5-fold after 24 h at 10 μM, while decreasing γGCL after 3 h at 10 μM[3].
Aurofusarin (2-256 µM; 6 h) inhibits the growth of Lactobacillus acidophilus in vitro with an IC50 of 8 µM, and had no effect on Escherichia coli, Staphylococcus aureus, or Salmonella typhimurium[5].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information
Your information is safe with us.